Administration of GSK2606414 or of another PERK inhibitor (AMG-44) also attenuated the immunosuppressive properties of MDSCs and TAMs, resulting in increased CD8+ T cell infiltration of tumor tissues and improved efficacy of anti-PD1 checkpoint therapy in mouse models [68,108,109]. The gene discussed is CD8A; the disease is neoplasm.